Nano-X Imaging Gets FDA Clearance for Nanox.ARC X

Ticker: NNOX · Form: 6-K · Filed: Apr 17, 2025 · CIK: 1795251

Sentiment: bullish

Topics: fda-clearance, medical-device, technology

TL;DR

FDA greenlights Nano-X Imaging's Nanox.ARC X for general medical imaging use.

AI Summary

On April 17, 2025, Nano-X Imaging Ltd. announced it received 510(k) clearance from the U.S. FDA for its Nanox.ARC X system. This clearance allows for the production of tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal, and paranasal sinus indications.

Why It Matters

This FDA clearance is a significant step for Nano-X Imaging, enabling the commercialization of their new multi-source digital tomosynthesis system for a wide range of medical imaging applications.

Risk Assessment

Risk Level: medium — While FDA clearance is positive, the company's success will depend on market adoption, manufacturing scale-up, and competition in the medical imaging sector.

Key Players & Entities

FAQ

What specific medical indications are covered by the FDA's 510(k) clearance for the Nanox.ARC X?

The FDA 510(k) clearance covers the production of tomographic images for general use, including the human musculoskeletal system and pulmonary, intra-abdominal and paranasal sinus indications.

What type of system is the Nanox.ARC X?

The Nanox.ARC X is a new multi-source digital tomosynthesis system.

When did Nano-X Imaging Ltd. announce this FDA clearance?

Nano-X Imaging Ltd. announced the FDA clearance on April 17, 2025.

What is the filing form used by Nano-X Imaging Ltd. for this report?

The filing form used is a 6-K, Report of Foreign Private Issuer.

What is the principal executive office address for Nano-X Imaging Ltd.?

The principal executive office is located at Ofer Tech Park, 94 Shlomo Shmeltzer Road, Petach Tikva, Israel, 4970602.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 17, 2025 regarding Nano-X Imaging Ltd. (NNOX).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing